Janus Henderson Group PLC Boosts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Janus Henderson Group PLC grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 399.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 69,485 shares of the specialty pharmaceutical company's stock after buying an additional 55,572 shares during the quarter. Janus Henderson Group PLC owned 0.22% of Collegium Pharmaceutical worth $2,686,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Gladius Capital Management LP bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $32,000. GAMMA Investing LLC raised its holdings in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 792 shares in the last quarter. CWM LLC increased its position in Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after purchasing an additional 736 shares during the period. nVerses Capital LLC raised its stake in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock worth $55,000 after buying an additional 1,600 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical by 61.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock worth $239,000 after purchasing an additional 2,352 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL traded down $0.33 during midday trading on Thursday, hitting $30.09. The company's stock had a trading volume of 622,619 shares, compared to its average volume of 446,102. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.57 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market cap of $970.40 million, a P/E ratio of 12.97 and a beta of 0.80. The firm's 50 day moving average is $33.48 and its 200-day moving average is $34.40.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. HC Wainwright lifted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, September 5th. Finally, Piper Sandler restated a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.60.

Insider Activity

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the business's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company's stock, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.